BioMarin Pharmaceutical Inc., commonly known by its ticker symbol BMRN, is a leading biotechnology company specializing in the development and commercialization of therapies for various rare genetic diseases. The company has its headquarters in San Rafael, California, and operates globally with a market presence in over 50 countries. BioMarin Pharmaceutical Inc., founded in 1996, is listed on the NASDAQ stock exchange and has been making significant strides in its field since its inception.
The company’s portfolio is primarily focused on providing innovative biopharmaceuticals for patients who often have few or no treatment options. These pharmaceuticals target a diversity of rare genetic diseases, including PKU, a metabolic disorder; hemophilia, a blood disorder; and achondroplasia, a bone-growth disorder among others.
BioMarin’s approach is based on pioneering first-to-market products. These include Palynziq and Kuvan for PKU, Naglazyme for MPS VI, a progressive, debilitating and life-threatening disease, and Vimizim for Morquio Syndrome, an inherited disorder of metabolism. They also have Brineura in their portfolio, the first and only treatment for CLN2 disease, a type of Batten disease. Each of these therapies had no approved treatment options prior to BioMarin's therapeutic applications.
In recent years, BioMarin has been working on innovative gene therapy approaches, most notably for hemophilia A. It is also looking into therapies for other deficiencies and disorders with its robust and diverse pipeline.
The company has built a reputation for developing novel drugs that address areas of high unmet medical need and obtaining approval for these drugs in global markets. It’s worth mentioning that BioMarin also invests heavily in research and development. The company employs a team of over 2,400 employees, including many leading scientists and researchers devoted to the discovery and advancement of novel therapeutics.
In conclusion, BioMarin Pharmaceutical Inc. stands out as a committed entity in the development and production of treatments for rare genetic disorders. Its innovative therapies have brought significant relief to patients worldwide and its consistent focus on research and development positions it aptly for continued advances in the biopharmaceutical industry. The company’s commitment to improving lives and its unwavering dedication to scientific innovation aptly justify its reputation as a leader in the biotech industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
BioMarin Pharmaceutical (BMRN) reported mixed Q3 2026 results, with adjusted profit exceeding expectations but sales falling short, leading to lowered full-year guidance. Despite short-term share price dips, the company is seen as potentially 21% undervalued, with a fair value of $73, driven by its rare disease franchise and pricing power. Investors are encouraged to assess the underlying data, rewards, and risks.
BioMarin Pharmaceutical (NASDAQ: BMRN) reported strong third-quarter 2026 financial results, with 32% year-over-year revenue growth, exceeding $1 billion for the first time. The company highlighted significant growth in its Metabolic Conditions business, driven by products like Galafold and Pombiliti and Opfolda, and discussed pipeline expansion with new investigational assets. BioMarin also updated its full-year 2026 revenue guidance to $3.8-$3.9 billion due to order timing and geopolitical factors, while accelerating cost synergies from the Amicus acquisition.
BioMarin Pharmaceutical Inc. has licensed exclusive worldwide rights, excluding Korea, to HM15421/GC1134A, an investigational Fabry disease enzyme replacement therapy, from GC Biopharma Corp. and Hanmi Pharm Co., Ltd. The deal includes a $70 million upfront payment and up to $405 million in milestones plus royalties. BioMarin will be responsible for clinical development, manufacturing, and commercialization outside Korea after the ongoing Phase I/II study.